SML1246

JNK-IN-8

≥96% (HPLC)

• Synonym(e): 3-[[4-(Dimethylamino)-1-oxo-2-buten-1-yl]amino]-N-[3-methyl-4-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide
• Empirische Formel (Hill-System): C₂₉H₂₉N₇O₂
• CAS-Nummer: 1410880-22-6
• Molekulargewicht: 507.59
• MDL-Nummer: MFCD22124890
• UNSPSC-Code: 12352200
• PubChem Substanz-ID: 329825741
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥96% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 20 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: O=C(C1=CC(NC(C=CCN(C)C)=O)=CC=C1)NC(C=C2C)=CC=C2NC3=NC=CC(C4=CC=CN=C4)=N3
• InChI: 1S/C29H29N7O2/c1-20-17-24(11-12-25(20)34-29-31-15-13-26(35-29)22-8-5-14-30-19-22)33-28(38)21-7-4-9-23(18-21)32-27(37)10-6-16-36(2)3/h4-15,17-19H,16H2,1-3H3,(H,32,37)(H,33,38)(H,31,34,35)
• InChIKey: GJFCSAPFHAXMSF-UHFFFAOYSA-N

Beschreibung

Anwendung

JNK-IN-8 has been used as an inhibitor to address the importance of JNK signaling in withaferin A (WFA)-induced apoptosis of myelodysplastic syndromes (MDS)-L cells.[1]

Biochem./physiol. Wirkung

JNK-IN-8 and lapatinib synergistically reduce cell viability in human triple negative breast cancers (TNBC) cell lines by inducing apoptosis. JNK-IN-8 and lapatinib result in accumulation of cytotoxic oxidative stress.[2]

JNK-IN-8 is a potent, selective and irreversible inhibitor of JNK1/2/3 that inhibits phosphorylation of c-Jun. JNK-IN-8 forms covalent bonds with a conserved cysteine residue.

JNK-IN-8 is a potent, selective and irreversible inhibitor of JNK1/2/3.

Sonstige Hinweise

JNK-IN-8 has been expertly reviewed and recommended by the Chemical Probes Portal. For more information, please visit the JNK-IN-8 probe summary on the Chemical Probes Portal website.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable